Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease

Ulcerative Colitis Clinical Trial

— EXPAND  

Official title:

A Randomized Controlled Trial on the Use of Postoperative Extended Venous Thromboprophylaxis in Patients With Inflammatory Bowel Disease: A Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03935451
• Other study ID #: 7043
• Status: Recruiting
• Phase: Early Phase 1
• Start date: September 1, 2021
• Est. completion date: February 1, 2026

Study information

• Verified date: January 2024
• Source: McMaster University
• Contact: Cagla Eskicioglu, MD MSc
• Phone: (905) 522-1155
• Email: eskicio[@]mcmaster.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Inflammatory bowel disease (IBD) is a relatively common disease that effects all age groups and carries significant morbidity and mortality. The initial treatment typically involves both short and long term medication, however when this is not enough to adequately control the disease, surgery is often required. The high morbidity and mortality rates are in part due to the increased rates of venous thromboembolism (VTE) such as deep vein thrombosis (DVT) or pulmonary embolism (PE) which have been shown to develop more frequently in IBD patients compared to the general population. Undergoing abdominal surgery has also been shown to independently increase rates of DVT and PE and since the majority of patients with IBD will undergo surgery at least once in their lifetime, the relative increased risk of developing a VTE is very high. The majority of DVT and PE events in the postoperative IBD population will occur after discharge from hospital and therefore carries significant morbidity and mortality risk in a unmonitored setting. Several studies have demonstrated the benefits and safety of twice daily dosing of oral extended VTE prophylaxis agents in orthopedic and cancer postoperative patients following discharge from hospital. There have been no randomized studies which have evaluated the use of extended postoperative VTE prophylaxis in IBD patients. The purpose of this randomized placebo controlled pilot trial will be to evaluate the efficacy and safety of postoperative VTE prophylaxis in IBD patients following abdominal surgery. If this pilot trial demonstrates efficacy in reducing postoperative DVT and PE rates, safety and feasibility, clinicians will be armed with the knowledge to pursue a larger multicenter randomized trial with the intent of reducing overall morbidity and mortality in this high risk population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 1, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• >18 years old
• Having documented pathological diagnosis of either Crohn's disease or ulcerative colitis.
• Open or laparoscopic abdominal gastrointestinal surgery
• Elective surgery
• Surgery occurring at Hamilton Health Sciences or St. Joseph's Healthcare Hamilton
• Negative urine beta-hCG for women of childbearing potential

Exclusion Criteria:

• Contraindication to use of postoperative thromboprophylaxis (ie. Previous bleeding on anticoagulation)
• Allergy to apixaban
• History of VTE
• Current clinically significant active bleeding, including GI bleeding
• Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
• Severe renal impairment (eCrCl <30 ml/min), or undergoing dialysis
• Lesions or conditions at increased risk of clinically significant bleeding (e.g. recent GI bleeding, recent ischemic or hemorrhagic cerebral infarction, active ulcerative GI disease, recent brain, spinal or ophthalmological surgery, bronchiectasis or history of pulmonary bleeding, thrombocytopenia or functional platelet defects, congenital or acquired coagulation disorder)
• Receiving any of the following drugs:
• Strong inhibitors of both CYP 3A4 and P-gp, such as azole-antimycotics (e.g. ketoconazole, itraconazole, voriconazole, or posaconazole), and HIV protease inhibitors (e.g. ritonavir)
• Strong inducers of both CYP 3A4 and P-gp (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John's Wort)
• Drug products affecting hemostasis (e.g. NSAIDs, ASA or other antiplatelet agents [e.g. ASA, clopidogrel, prasugrel, ticagrelor], SSRIs, or SNRIs)
• Any other anticoagulant, including unfractionated heparin, LMWH, heparin derivatives, or oral anticoagulants (e.g. warfarin, dabigatran, rivaroxaban)
• Currently receiving therapy for any type of malignancy (e.g. colorectal, breast, lung)
• History of colorectal cancer
• Emergency surgery
• Patients with an indication for anticoagulation before surgery (atrial fibrillation, etc.)
• Enrolled in any other clinical trials or prospective studies where similar outcomes are measured
• Pregnant (i.e. positive pregnancy test and/or self-reported) and/or breastfeeding
• Women of childbearing potential unwilling/unable to participate in appropriate family planning during the treatment period

Related Conditions & MeSH terms

• Colorectal Disorders
• Crohn Disease
• Embolism
• IBD
• Inflammatory Bowel Diseases
• Pulmonary Embolism
• Thromboembolism
• Ulcerative Colitis
• Venous Thromboembolism

Intervention

Drug:
• Apixaban 2.5 milligram
2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
• Placebo Oral Tablet
placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration

Locations

Country	Name	City	State
Canada	Juravinski Hospital	Hamilton	Ontario
Canada	St. Joseph's Healthcare	Hamilton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
McMaster University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of post operative venous thromboembolism events (DVT/PE) in in patients with Inflammatory Bowel Disease	The primary efficacy outcome will be a composite of symptomatic proximal DVTs of the upper and lower extremities, splanchnic VTE, nonfatal PE (segmental or greater artery), and death from PE and death from any cause within 3 months following hospital discharge.	3 months post operatively
Primary	Incidence of bleeding while undergoing treatment with oral anticoagulant or placebo.	The primary safety outcome will be bleeding reported during treatment, including major bleeding, clinically relevant non-major (CRNM) bleeding, minor bleeding, and the composite of major bleeding and CRNM bleeding.	3 months post operatively
Secondary	Incidence of surgical complications related to post operative anticoagulation	The secondary outcome will include surgical complications related to anticoagulation (intra-abdominal bleeding, surgical site bleeding), and arterial thromboembolic events such as acute ischemic stroke, myocardial infarction, and other VTE (upper extremity and splanchnic veins).	3 months post operatively